Breast Cancer, Circulating Tumor Cell, Diagnoses Disease, Gastric Cancer, Volatile Organic Chemicals
Conditions
Keywords
CTCs, VOCs, Breast cancer, Gastric cancer, diagnoses
Brief summary
Early diagnosis of malignant tumors is pivotal for improving their prognoses. Circulating tumor cells (CTC) in peripheral blood and Volatile organic compounds (VOCs) in exhaled breath are newly developed diagnosis method. Due to the low percentage of CTCs in peripheral blood of cancer patients and the surface structure of lymphocytes (especially megakaryocytes) is often confused with tumor cells, CTC has a high false positive and negative rate. In recent years, the detection of volatile organic compounds (VOCs) in exhaled breath as a simple and noninvasive method has shown broad application prospects in the diagnosis of various diseases. A series of studies of VOCs diagnosing solid tumors the investigators had conducted in the past decade show that VOCs can not only distinguish different types of tumors, but also can make a distinction between different stages. This study was to compare CTC and VOCs with clinical samples. Predictive models will be built employing discriminant factor analysis (DFA) pattern recognition method. Sensitivity and specificity will be determined using leave-one-out cross-validation or an independent blind test set.
Detailed description
200 patients with definitive diagnoses will be enrolled and the alveolar exhaled breath samples and peripheral venous blood will be collected. Two blood samples and two breath samples will be collected from each patient. One blood sample will be send to CTC tests for a blind test and the other will be used for headspace VOCs analyses. One breath sample was used for analysis with the Nano-sensors array, and the other was used for gas chromatography coupled with mass spectrometry (GC-MS) analysis. The VOCs samples were collected using sorbent tubes at a total flow through sorption trap of 200ml/min, then will be send to Israel Institute of Technology for further test.
Interventions
DIAGNOSTIC_TESTCirculating tumor cells, Volatile organic compounds
Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
Sponsors
Technion, Israel Institute of Technology
Anhui Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* 18-75 years * Definitive diagnosis of gastric cancer, breast cancer,benign breast disease and gastric lesions * ECOG(Eastern Cooperative Oncology Group) scores ≤ 2
Exclusion criteria
* Other palliative chemotherapy and radiotherapy for this cancer * Other cancer * Diabetes, Fatty liver * Autoimmune disease * Pulmonary ventilation dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Discrimination between Malignant and Benign Gastric/Breast Lesions and normal group with each diagnostic method (Na-nose/GC-MS/CTC) | From June 15,2019 to June 1,2020 | Exhaled breath samples and peripheral venous blood collected will be used to build predictive models employing discriminant factor analysis (DFA) and thereafter examine the sensitivity and specificity of model identification. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comprehensive diagnostic model of VOCs and CTCs | From June 1,2020 to Dec 31,2020 | Organize predictive models of VOCs/CTCs and establish Comprehensive Diagnostic Model. |
Contacts
Primary ContactChuyang Bao, MD
Backup ContactHu Liu, MD
Outcome results
None listed